Interferon-α enhances the cytotoxic and cytostatic activities of chemotherapeutic drugs in human myeloid leukemia cells

Journal of Interferon and Cytokine Research

Volumn 16, Issue 2, 1996, Pages 139-146

  Hassan, H T ^a,b   Grell, S ^a   Borrmann Danso, U ^a   Freund, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYTARABINE; DAUNORUBICIN; RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SURVIVAL;

EID: 0030031370     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.139     Document Type: Article

References (36)

1. FREUND, M., and HUBER, C. (1993). Interferon-alpha has become a standard in the treatment of chronic myeloid leukemia. Semin. Hematol. 30(Suppl. 3); 1-5.
2. KANTAIJIAN, H., and TALPAZ, M. (1991). Treatment of chronic myelogenous leukemia. In: Therapy of Hematopoietic Neoplasia. EJ Freireich and H Kantarijian (eds.) New York: Dekker, pp. 105-174.
3. KLOKE, O. (1993). Combination therapy for CML with Inter feron alpha and other cytokines. Semin. Hematol. 30(Suppl. 3), 22-23.
4. + chronic myelogenous leukemia (CML) in the CML 88 France multicenter randomised protocol: hydroxyurea (HU) + interferon-alpha 2b (IFN) with or without cytosine arabinoside (Ara-C). Proc. AACR 35(411), 2453A.
5. FREUND, M., HILD, F., GROTE-METKE, A., et al. (1993). Combination of chemotherapy and interferon-alpha 2b in the treatment of chronic myelogenous leukaemia. Semin. Hematol. 30(Suppl. 3), 11-13.
6. LIBERATI, A.M., MORRA, E., LAZZARINO, M., et al. (1994). Response to low-dose Ara-C + IFN-alpha in advanced and second chronic phase chronic myeloid leukemia. Br. J. Haematol. 171(Suppl. 1), 668A.
7. LAZZARINO, M., MORRA, E., MERANTE, P., et al. (1994). Response to different treatments in chronic myelogenous leukemia (CML) according to risk assessment at diagnosis: survival advantage with interferon-alpha therapy. Br. J. Haematol. 171(Suppl. 1), 666A.
8. BACARANI, M., and RUSSO, D. (1994). Alpha-interferon for treatment of chronic myeloid leukaemia. Br. J. Haematol. 164(Suppl. 1), 640A.
9. MARTINEZ, J.A., MARTIN, G., SANZ, G.F., SEMPERE, A., JARQUE, I., DE LA RUBIA, J., and SANZ, M.A. (1991). A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J. Clin. Oncol. 9, 39-43.
10. VOGLER, W.R., HARRINGTON, D.P., WINTON, E.F., LAXARUS, H.M., BENNETT, J.M., CASSILETH, P.A., and OKEN, M.M. (1992). Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia 6, 1072-1075.
11. ARCHIMBAUD, E., ANGLARET, B., THOMAS, X., DEVAUX, Y., FFRENCH, M., SEBBAN, C., TRONCY, J., and FIERE, D. (1992). Continuous-infusion daunorubicin and carboplatin for high-risk AML in the elderly. Leukemia 6, 776-779.
12. MARSH, J.H., KREIS, W., BARILE, B., AKERMAN, S., SCHULMAN, P., ALLEN, S.L., DEMARCO, L.C., SCHUSTER, M.W., and BUDMAN, D.R. (1993). Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of CML with the combination of cytarabine, tetrahydrouridine and carboplatin. Cancer Chemother. Pharmacol. 31, 481-184.
13. LEE, E.J., BECK, K., CARTER, C., HODGES, S., and SCHIFFER, C.A. (1993). A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia. Leukemia 7, 1500-1053.
14. SANZ, M.A., SANZ, G.F., MARTINEZ, J.A., SENENT, L., LOPEZ, F., PALAU, J., MARTIN, G., and JARQUE, I. (1992). Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia. Ann. Oncol. 3, 39-42.
15. BENGER, A.M., BROWMAN, G.P., WALKER, I.R., MEYER, R.M., WILSON, W.E., and MCBRIDE, J.A. (1992). A pilot study of carboplatin augmentation therapy for patients with poor ANLL. Leuk. Res. 16, 159-163.
16. BONANAD, S., BLANQUER, A., MARTIN, G., MERTINEZ, J., SANZ, G.F., and SANZ, M.A. (1994). Carboplatin-based regimens for treatment of myelodysplastic syndromes (MDS) and secondary AML. Br. J. Haematol. 3(Suppl. 1), 12A.
17. VOGLER, W.R. (1993). High-dose carboplatin in treatment of hematologic malignancies. Oncology 50(Suppl. 2), 42-46.
18. ETTINGER, L.J., KRAILO, M.D., GAYNON, P.S. and HAMMOND, G.D. (1993). A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. A report from the Childrens Cancer Group. Cancer 72, 917-922.
19. KANO, Y., AKUTSU, M., SUZUKI, K., and YOSHIDA, M. (1993). Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk. Res. 17, 113-119.
20. HASSAN, H.T., and MAURER, H.R. (1992). Synergism between recombinant human interferon-alpha and carboplatin in inhibiting K562 human myeloid leukaemia clonogenic cells: new potential therapeutic development. Leuk. Res. 16, 419-420.
21. REES, J.K.H. (1990). Chemotherapy of the leukaemias. In: New Approaches to the Treatment of Leukemia, Freireich (ed.) Berlin: Springer Verlag, pp.5-77.
22. HASSAN, H.T., VEIT, A., and MAURER, H.R. (1991). Recombinant human GM-CSF significantly enhances the cytostatic activity of cell cycle specific antileukemic drugs in HL-60 human myeloid leukaemic cells in agar capillary clonogenic microassay. Anticancer Res. 11, 481-486.
23. HASSAN, H.T., and MAURER, H.R. (1991). Effects of recombinant human cytokines on cytarabine activity in K562 human myeloid leukaemia cells. Chemotherapy 37, 441-448.
24. HEGEWISCHE, S., BRESSLER, J., HAIMI, J., SOUZA, L., and ANDREEFF, M. (1988). Induction of differentiation by G-CSF, GM-CSF and cytosine arabinoside in human myeloid leukaemia cell line KG1. Proc. AACR 29(368), 1465A.
25. DEWITTE, T., NUUS, P., and HAENEN, C. (1988). Recombinant human GM-CSF enhances sensitivity of leukaemic clonogenic cells to long term low dose cytosine arabinoside with sparing of the normal clonogenic cells. Behring Inst. Mitt. 83, 301-308.
26. BELLOC, F., LACOMBE, F., VIAL, J.P., SCHMIT, P., DUMAIN, P., BERNARD, P., and REIFFERS, J. (1994). Flow cytometric study of the induction of the apoptosis by anthracyclines and Ara-C in the U937 cell line. Proc. AACR 35(318), 1890A.
27. HASSAN, H.T., GRELL, S., BORRMANN-DANSO, U., and FREUND, M. (1994). Interleukin-4 inhibits the proliferation of MHH225 human myeloid leukaemia megakaryoblastic cell line. Hematol. Oncol. 12, 61-66.
28. HASSAN, H.T., and REES, J.K.H. (1990). The relation between age and blast cell differentiation in acute myeloid leukaemia patients. Oncology 47, 439-442.
29. HASSAN, H.T., VEIT, A.F., and MAURER, H.R. (1991). Synergistic interactions between differentiation inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic microassay. J. Clin. Oncol. Cancer Res. 117, 227-231.
30. WALDER, S., and SCHWARTZ, E.L. (1990). Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 50, 3473-3486.
31. ELIAS, L., HOFFMAN, R., BOSWELL, S., TENSEN, L., and BONNEM, E.M. (1987). A trial of recombinant alpha-interferon in the MDS. I. Clinical results. Leukemia 1, 105-110.
32. AUL, C., GATTERMANN, N., and SCHNEIDER, W. (1991). Treatment of advanced myelodysplasia with recombinant interferon-alpha. Eur. J. Haematol. 46, 11-16.
33. MONTSERRAT, E., VILLAMOR, N., URBAO-ISPIZUA, A., et al. (1991). Treatment of early stage B-CLL with interferon-alpha after chlorambucil reduction of the tumoural mass. Ann. Hematol. 63, 15-19.
34. HASSAN, H.T., TSIRIYOTIS, C., MAURER, H.R., and SPANDIDOS, D. (1992). Effects of recombinant human interferon-alpha, beta and gamma on the antiproliferative activity of cytarabine in K562 human myeloid leukaemia lonogenic cells. Hematol. Oncol. 10, 117-124.
35. SLATER, L.M., WETZEL, M.W., and CESARIO, T. (1981). Combined interferon-antimetabolite therapy of murine L1210 leukaemia. Cancer 48, 5-9.
36. HASSAN, H.T. (1993). Synergism between differentiation agents: preclinical and clinical studies in myeloid leukaemia. In: The Pharmacology of Cell Differentiation. R.A. Rifkind (ed.) Amsterdam: Elsevier, pp. 277-294.